October 31, 2023 01:19 PM EDT
Pharma
FDA+

FDA push­es can­cer drug de­vel­op­ers to in­clude over­all sur­vival da­ta more fre­quent­ly

Zachary Brennan

Senior Editor

For years, the FDA has al­lowed pro­gres­sion-free sur­vival to serve as both a pri­ma­ry and sur­ro­gate end­point to sup­port speedy new can­cer drug ap­provals. But …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times